SEQUA.BR

Sequana Medical NV [SEQUA.BR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SEQUA.BR Stock Summary

Top 10 Correlated ETFs

SEQUA.BR

Top 10 Correlated Stocks

SEQUA.BR

In the News

SEQUA.BR Financial details

Company Rating
-
Market Cap
45.37M
Income
-56.7M
Revenue
1.36M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
70
Optionable
No
Shortable
Yes
Earnings
05 Sep 2024
P/E
-3.12
Forward P/E
-
PEG
-0.48
P/S
129.17
P/B
-44.62
P/C
-
P/FCF
-4.23
Quick Ratio
1.25
Current Ratio
1.52
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.22
EPS next Y
-
EPS next Q
-
EPS this Y
-9.63%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
0%
Revenue last 5Y
-6.01%
Revenue Q/Q
-14.67%
EPS Q/Q
-12.31%
-
-
-
-
SMA20
47.92%
SMA50
37.86%
SMA100
-18.86%
Inst Own
-
Inst Trans
-
ROA
-118%
ROE
2093%
ROC
-2.61%
Gross Margin
78%
Oper. Margin
-3077%
Profit Margin
-3334%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.36-5.18
52W High
-72.8%
52W Low
+36%
RSI
56.4
Rel Volume
0.98
Avg Volume
108.07K
Volume
105.8K
Perf Week
-11.11%
Perf Month
36.27%
Perf Quarter
-48.29%
Perf Half Y
-58.41%
-
-
-
-
Beta
0.834
-
-
Volatility
0.07%, 0.2%
Prev Close
3.82%
Price
1.36
Change
0.74%

Something similar

Top by Market Cap
TSLA
MSF.DE
BRYN.DE
BRK-B
GOOG
Top Correlated ETFs
IHHG.L
IBC2.DE
MON100.NS
IHYU.L
SYBD.DE
Top Correlated Stocks
6058.T
1972.T
MLPHO.PA
AAREYDRUGS.NS
GOS.DE
Similar Market Cap
XAIR
RIET
FARM
0379.HK
CUBA

Company Profile

Healthcare Medical - Devices
  • Volume Average 108.07K
  • Market Capitalization 45.37M
  • Employee 70
  • CEO Mr. Ian Crosbie
  • Headquarters Gent,BE
  • IPO Date 2019-02-11
  • Website https://www.sequanamedical.com

Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.